US 12,478,672 B2
Use of triplex CMV vaccine in CAR T cell therapy
Don J. Diamond, Duarte, CA (US); Xiuli Wang, Temple City, CA (US); and Stephen J. Forman, Duarte, CA (US)
Assigned to City of Hope, Duarte, CA (US)
Filed by City of Hope, Duarte, CA (US)
Filed on Jul. 19, 2023, as Appl. No. 18/354,849.
Application 18/354,849 is a continuation of application No. 17/572,496, filed on Jan. 10, 2022, abandoned.
Application 17/572,496 is a continuation of application No. 17/006,758, filed on Aug. 28, 2020, abandoned.
Application 17/006,758 is a continuation of application No. 16/343,701, abandoned, previously published as PCT/US2017/057433, filed on Oct. 19, 2017.
Claims priority of provisional application 62/410,372, filed on Oct. 19, 2016.
Prior Publication US 2024/0016930 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/245 (2006.01); A61K 39/285 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 40/46 (2025.01); A61P 31/20 (2006.01); A61P 35/00 (2006.01); C07K 14/00 (2006.01); C07K 14/005 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 14/73 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01)
CPC A61K 39/39558 (2013.01) [A61K 39/12 (2013.01); A61K 39/245 (2013.01); A61K 39/285 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61K 40/46 (2025.01); A61P 31/20 (2018.01); A61P 35/00 (2018.01); C07K 14/00 (2013.01); C07K 14/005 (2013.01); C07K 14/7051 (2013.01); C07K 14/70514 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C12N 5/0636 (2013.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/585 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2710/16122 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/24134 (2013.01); C12N 2710/24143 (2013.01)] 10 Claims
 
1. A method for treating a patient suffering from lymphoma expressing CD19 comprising:
(a) providing a composition comprising a population of T cells expressing both a chimeric antigen receptor (CAR) targeted to CD19 and a T cell receptor that binds a cytomegalovirus (CMV) antigen pp65;
(b) administering the composition of part (a) to the patient; and
(c) administering to the patient a viral vector encoding:
(i) CMV pp65 and
(ii) a fusion protein comprising exon 4 of CMV protein IE1 (e4) and exon 5 of CMV protein IE2 (e5).